Comparison of Two Different Doses of Bemiparin in COVID-19

Clinica Universidad de Navarra, Universidad de Navarra164 enrolled

Overview

Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

164

Conditions

COVID-19

Interventions

Bemiparin sodiumDRUG

Prophilactic vs full-dose for 10 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age (equal or more than 18 yo) * Hospitalization at conventional wards due to COVID-19 related mild or moderate pneumonia (CURB65\<3 points; Sat. O2\>90%) * 3-4 points according to the WHO ordinal scale. * Confirmed COVID-19 (PCR or other validated test) * D-dimer \>500 ng/mL * Sign of informed consent * The patient is able, according to investigator's opinion, to deal with all the requirements of the clinical trial. Exclusion Criteria:

Locations (12)

Hospital Rey Juan Carlos

Móstoles, Madrid, Spain

NOT_YET_RECRUITING

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

RECRUITING

Outcomes

Primary Outcomes

Clinical deterioration

Combined outcome that includes number of patients who suffer any of the following: Death, ICU admission, mechanical ventilatory support, progression to moderate or severe ARDS (according to Berlin criteria) or arterial or venous thrombosis.

Time frame: 10 days

Central Contacts

Ramon Lecumberri, MD, PhD

CONTACT

+34 948296397 rlecumber@unav.es

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.